Hematopoietic engraftment and GVHD by immune cell type
| Variable . | . | Multivariable . | ||
|---|---|---|---|---|
| Total no. of patients . | RR . | 95% CI . | P . | |
| Neutrophil engraftment at day 42 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.31-0.82 | <.01 |
| Lower (<43.8) | 31 | 0.51 | ||
| Total CD8+ T cells (CD3+CD4-CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 1.02-2.13 | .04 |
| Lower (<34.8) | 66 | 1.47 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.42-1.27 | .27 |
| Lower (<8.9) | 16 | 0.73 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.36-1.13 | .12 |
| Lower (<1.3) | 15 | 0.64 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.56-1.15 | .24 |
| Lower (<0.4) | 56 | 0.80 | ||
| Platelet engraftment at day 180 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.36-0.86 | .01 |
| Lower (<43.8) | 31 | 0.56 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.56-1.32 | .48 |
| Lower (<34.8) | 66 | 0.86 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.47-1.45 | .51 |
| Lower (<8.9) | 16 | 0.83 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.38-1.36 | .31 |
| Lower (<1.3) | 15 | 0.72 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.50-1.02 | .06 |
| Lower (<0.4) | 56 | 0.71 | ||
| Grade II-IV acute GVHD at day 180 | ||||
| Total NK cells (CD3-CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.52-2.23 | .85 |
| Lower (<43.8) | 31 | 1.08 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.44-2.05 | .90 |
| Lower (<34.8) | 66 | 0.95 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.46-2.66 | .81 |
| Lower (<8.9) | 16 | 1.11 | ||
| CD4+ naive T cells (CD45RA+ CD27+) | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.27-1.99 | .54 |
| Lower (<1.3) | 15 | 0.73 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.59-2.19 | .70 |
| Lower (<0.4) | 56 | 1.14 | ||
| Chronic GVHD at 1 y | ||||
| Total NK cells (CD3-CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.67-4.45 | .26 |
| Lower (<43.8) | 31 | 1.72 | ||
| Total CD8+ T cells (CD3+CD4-CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.61-3.02 | .45 |
| Lower (<34.8) | 66 | 1.36 | ||
| Total CD4+ T cells (CD3+CD4+CD8-), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 1.02-5.79 | .04 |
| Lower (<8.9) | 16 | 2.43 | ||
| CD4+ naive T cells (CD45RA+ CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 1.63-7.98 | <.01 |
| Lower (<1.3) | 15 | 3.60 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.92-3.96 | .08 |
| Lower (<0.4) | 56 | 1.91 | ||
| Variable . | . | Multivariable . | ||
|---|---|---|---|---|
| Total no. of patients . | RR . | 95% CI . | P . | |
| Neutrophil engraftment at day 42 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.31-0.82 | <.01 |
| Lower (<43.8) | 31 | 0.51 | ||
| Total CD8+ T cells (CD3+CD4-CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 1.02-2.13 | .04 |
| Lower (<34.8) | 66 | 1.47 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.42-1.27 | .27 |
| Lower (<8.9) | 16 | 0.73 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.36-1.13 | .12 |
| Lower (<1.3) | 15 | 0.64 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.56-1.15 | .24 |
| Lower (<0.4) | 56 | 0.80 | ||
| Platelet engraftment at day 180 | ||||
| Total NK cells (CD3−CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.36-0.86 | .01 |
| Lower (<43.8) | 31 | 0.56 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.56-1.32 | .48 |
| Lower (<34.8) | 66 | 0.86 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.47-1.45 | .51 |
| Lower (<8.9) | 16 | 0.83 | ||
| CD4+ naive T cells (CD45RA+CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.38-1.36 | .31 |
| Lower (<1.3) | 15 | 0.72 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.50-1.02 | .06 |
| Lower (<0.4) | 56 | 0.71 | ||
| Grade II-IV acute GVHD at day 180 | ||||
| Total NK cells (CD3-CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.52-2.23 | .85 |
| Lower (<43.8) | 31 | 1.08 | ||
| Total CD8+ T cells (CD3+CD4−CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.44-2.05 | .90 |
| Lower (<34.8) | 66 | 0.95 | ||
| Total CD4+ T cells (CD3+CD4+CD8−), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 0.46-2.66 | .81 |
| Lower (<8.9) | 16 | 1.11 | ||
| CD4+ naive T cells (CD45RA+ CD27+) | ||||
| Higher (≥1.3) | 139 | 1.0 | 0.27-1.99 | .54 |
| Lower (<1.3) | 15 | 0.73 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.59-2.19 | .70 |
| Lower (<0.4) | 56 | 1.14 | ||
| Chronic GVHD at 1 y | ||||
| Total NK cells (CD3-CD56+), cells/μL | ||||
| Higher (≥43.8) | 126 | 1.0 | 0.67-4.45 | .26 |
| Lower (<43.8) | 31 | 1.72 | ||
| Total CD8+ T cells (CD3+CD4-CD8+), cells/μL | ||||
| Higher (≥34.8) | 88 | 1.0 | 0.61-3.02 | .45 |
| Lower (<34.8) | 66 | 1.36 | ||
| Total CD4+ T cells (CD3+CD4+CD8-), cells/μL | ||||
| Higher (≥8.9) | 138 | 1.0 | 1.02-5.79 | .04 |
| Lower (<8.9) | 16 | 2.43 | ||
| CD4+ naive T cells (CD45RA+ CD27+), cells/μL | ||||
| Higher (≥1.3) | 139 | 1.0 | 1.63-7.98 | <.01 |
| Lower (<1.3) | 15 | 3.60 | ||
| Total B cells (CD19+), cells/μL | ||||
| Higher (≥0.4) | 97 | 1.0 | 0.92-3.96 | .08 |
| Lower (<0.4) | 56 | 1.91 | ||
RR was adjusted for donor type.